Both ACKR2 and CCR1 have been shown to be important in the progression of breast cancer; therefore, understanding early interactions between these receptors could reveal key insights, which drive later pathology (Kitamura et al., 2015; Shin et al., 2017; Hansell et al., 2018). This evidence concerns the gene ACKR2 and breast carcinoma.